Bladder Cancer
November 13
3 min read
On November 13, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhibitor durvalumab (Imfinzi) in combination with the antibody-drug conjugate enfortumab vedotin-ejfv as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment after radical cystectomy, for the treatment of adult patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or who have refused cisplatin-based chemotherapy.